<p>We analyzed the performance of CPD items obtained from the Beckman Coulter Unicel DxH800 and hematopoietic progenitor cell (HPC) count offered by the Sysmex XN Analyzer as a prediction marker for successful hematopoietic stem cell (HSC) mobilization in autologous stem cell transplantation (ASCT)-scheduled hematologic malignancy patients. From Febrary 2023 to September 2024, total 50 ASCT-eligible hematologic malignancy patients were prospectively enrolled. During six consecutive evaluation days, the measurement of HPC, WBC, stem cell index (SCI), neutrophil immaturity index, the standard deviation of the conductivity of early granulocytic cells (SD-C-EGC), mean of the conductivity of early granulocytic cells (MN-C-EGC), and flow cytometric CD34 + cell count was performed, and the performance of each item were compared. Among estimated item, the HPC count (AUC 0.933, best cutoff ≥ 43 × 10⁶/L), SD-C-EGC (AUC 0.878, best cutoff ≥ 3.37), SCI (AUC 0.844, best cutoff ≥ 8.63) performed well in the prediction of successful HSC mobilization. The performance of SCI and SD-C-EGC was not significantly inferior to that of HPC count and these three items could predict successful HSC mobilization results at least one day before HSC collection. The use of SD-C-EGC in combination with HPC could reduce false negative rate from 7.9% to 2.6% when compared to using HPC alone. Both SD-C-EGC and SCI obtained from the DxH800 analyzer as well as the HPC count performed well in the prediction of successful HSC mobilization and could predict with time advantage. The use of SD-C-EGC in combination with the HPC would reduce false negative rate of the HPC count as a prediction marker.</p>